Phase1/-2 study of pomalidomide in myelofibrosis

Ruben A. Mesa, Animesh D. Pardanani, Kebede Hussein, Wenting Wu, Susan Schwager, Mark R. Litzow, William J. Hogan, Ayalew Tefferi

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


We conducted a dose-escalation study to see if higher doses of Pomalidomide (previously shown to be safe and effective for myelofibrosis-associated anemia at 0.5 mg/day [with prednisone] or 2.0 mg/day) increased anemia responses. 3.0 mg/d given for 21 of 28 consecutive days was the maximum-tolerated dose (MTD), with myelosuppression being dose limiting. Nonresponders at the MTD had their dose decreased and the therapy interval increased to daily. Seven of 19 subjects had an anemia-response and two had a spleen response. Most responses occurred after dose-reduction to 0.5 mg/d, suggesting higher doses are associated with increasing myelosuppression without increasing (or possibly decreasing) efficacy.

Original languageEnglish (US)
Pages (from-to)129-130
Number of pages2
JournalAmerican journal of hematology
Issue number2
StatePublished - Feb 2010

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Phase1/-2 study of pomalidomide in myelofibrosis'. Together they form a unique fingerprint.

Cite this